This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.

Below are top 10 S&P 500 stock gainers for the week ended Nov. 21:

Solventum to Buy Private Wound Care Firm Acera for up to $850M, Sets $1 Billion Share Repurchase Program

Solventum, 3M’s (MMM) healthcare spinoff, on Thursday announced an agreement to acquire Acera Surgical, a privately owned wound care company, in an all-cash deal worth up to $850M.

Solventum board has approved a share repurchase program, which authorizes the company to purchase up to $1 billion of its outstanding common stock.

Solventum expects to begin repurchasing shares in 2026 and had ~173.4 million shares outstanding as of October 31, 2025.

Solventum shares jumped 9.6% this week.

Regeneron Stock Rises as EYLEA HD Gets FDA Approval for New Indication

Regeneron Pharmaceuticals stock rose 9% this week as the FDA approved its EYLEA HD injection for treating macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period.

Wells Fargo & Company raised their price target on Regeneron stock from $615.00 to $700.00. Wells Fargo & Company currently has an equal weight rating on the stock.

Bernstein SocGen Group reiterated an Outperform rating and $818.00 price target on Regeneron Pharmaceuticals following positive developments for its Eylea HD treatment.

Google Surpasses Microsoft in Market Value

Alphabet, Google’s parent company, surpassed Microsoft as the third-largest U.S. company by market capitalization on Friday. Nvidia and Apple rank first and second, respectively.

Alphabet closed 3.5% higher Friday, giving it a market value of $3.62 trillion. The shares jumped 8.4% this week.

The milestone says more about Google’s successes than Microsoft’s struggles. Microsoft stock has stagnated since the summer, but shares remain up 11% this year, in line with the S&P 500.

Ross Stores Lifts Annual Profit Forecast on Strong Demand for Discount Goods

Ross Stores raised its annual profit forecast on Thursday, betting on resilient demand for its discounted apparel and accessories ahead of the holiday season amid looming macroeconomic uncertainties.

Shares of the company, which also beat estimates for third-quarter sales, were up 8.4% this week.

Off-price retailers such as Ross Stores have been attracting budget-conscious customers as shoppers increasingly seek branded goods at lower prices due to persistent inflation and volatile trade policy.

Medtronic Raises Annual Sales Growth Forecast on Heart Devices Demand

Medtronic beat second-quarter estimates and raised annual sales growth forecast on Tuesday, driven by strong demand for heart devices, sending its shares up 5.6% this week.

Investor expectations for medical device makers have remained high in recent quarters, boosted by robust demand for surgical procedures, particularly among older adults, greater physician adoption and advances in technology.

Sales in Medtronic's cardiovascular segment jumped 10.8% to $3.44 billion during the quarter, powered by its pulsed field ablation (PFA) portfolio used to treat irregular heart rhythms.

Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era

Merck shares rose 5.2% this week in response to positive results from a trial of the heart drug that the company is counting on for much of its growth.

Patent protection on Keytruda, the cancer treatment that accounts for nearly half of Merck’s revenue, is nearing its end, so the company is rushing to buy and develop alternatives. It has turned significant focus to the heart drug Winrevair, which is anticipated to be a top seller.

Analysts now expect Winrevair sales to surpass $5.5 billion in 2030, according to FactSet, up from just over $400 million last year.